alpha-Synuclein – Talk Bio

Novartis Takes Another Shot at Alpha-Synuclein With $2.2B Arrowhead CNS Deal

1 week ago talkbio0Tagged alpha-Synuclein, ARO-SNCA, Arrowhead Pharmaceuticals, biotech partnerships, Gene Silencing, Nerve Degeneration, Novartis, Parkinson 's disease, RNA Interference, TRiM platform

Novartis; Arrowhead Pharmaceuticals; alpha-synuclein; Parkinson’s disease; RNA interference (RNAi); gene silencing; ARO-SNCA; TRiM platform; neurodegeneration; biotech partnerships

Roche’s Prasinezumab Fails Primary Endpoint in Phase 2b Parkinson’s Trial, Shows Promising Trends

9 months ago talkbio0Tagged alpha-Synuclein, PADOVA study, Parkinson 's disease, Phase 2b Trial, Prasinezumab, Prothena, Roche (company)

Roche, Prothena, Parkinson’s disease, prasinezumab, alpha-synuclein, phase 2b trial, PADOVA study

Vanqua Bio Advances Experimental Parkinson’s Therapy with VQ-101, Bolsters Leadership Team

11 months ago talkbio0Tagged Accumulation, alpha-Synuclein, Bio, Clinical Trials, GBA gene, GCase, GCase activator, Lysosomal dysfunction, Neurodegenerative Disorders, Parkinson 's disease, Vanqua, VQ-101

Vanqua Bio, VQ-101, Parkinson’s disease, GBA gene mutations, GCase activator, Neurodegenerative diseases, Clinical trials, Lysosomal dysfunction, Alpha-synuclein accumulation